Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Becton Dickinson's Current Accrued Expense for the quarter that ended in Jun. 2026 was CHF4,881 Mil.
Becton Dickinson's quarterly Current Accrued Expense
declined
from Dec. 2025 (CHF4,891 Mil) to Mar. 2026 (CHF4,672 Mil) but then
increased
from Mar. 2026 (CHF4,672 Mil) to Jun. 2026 (CHF4,881 Mil).
Becton Dickinson's annual Current Accrued Expense
increased
from Sep. 2023 (CHF3,346 Mil) to Sep. 2024 (CHF4,000 Mil) but then
declined
from Sep. 2024 (CHF4,000 Mil) to Sep. 2025 (CHF3,542 Mil).
Becton Dickinson Current Accrued Expense Related Terms
Becton Dickinson Current Accrued Expense Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Becton Dickinson Current Accrued Expense Calculation
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of CHF4,881 Mil mean?
Becton Dickinson (XSWX:BDX) has a Current Accrued Expense of CHF4,881 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Becton Dickinson and its competitors.
Is Becton Dickinson's Current Accrued Expense too high?
Becton Dickinson's current Current Accrued Expense is CHF4,881 Mil. Overall, Becton Dickinson has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's Current Accrued Expense compare to MDLN and RMD?
Becton Dickinson's Current Accrued Expense of CHF4,881 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Becton Dickinson and its competitors. Becton Dickinson's current Current Accrued Expense is CHF4,881 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current Current Accrued Expense of CHF4,881 Mil. The stock's GF Value™ is CHF155.68, compared to a current price of CHF148.66 — trading 4.5% below its estimated fair value. The current Current Accrued Expense is CHF4,881 Mil. Becton Dickinson's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current Current Accrued Expense is CHF4,881 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of CHF148.66 is trading 4.5% below its estimated GF Value™ of CHF155.68.
Key valuation signals for XSWX:BDX:
Current Accrued Expense: CHF4,881 Mil
GF Value™: CHF155.68 vs. price of CHF148.66 (4.5% below fair value)
No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
77GF Score
Get the complete analysis for XSWX:BDX
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BDX has been successfully added to your 
